ProMetic and American Red Cross form joint venture:
This article was originally published in Clinica
Montreal, Canada-based ProMetic Life Sciences and the American Red Cross (ARC) have formed a joint venture company. The new company will be aimed at researching, developing and commercialising diagnostic and removal systems for and other pathogens that may cause transmissible spongiform encephalopathies (TSEs) and certain viruses. ProMetic and ARC will each contribute intellectual property and technical expertise.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.